HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Commits To Personal-Care Fragrance Disclosure; Who’s Next?

This article was originally published in The Rose Sheet

Executive Summary

Unilever’s announcement that it will disclose fragrance ingredients in personal-care products is a potential game-changer for the industry, representing a heretofore unseen level of transparency from a leading multinational.

You may also be interested in...



Health, Beauty And Wellness News: FDA Shutdown, Kemin Marketing VP, More

FDA cosmetics operations likely shuttered with shutdown; Stomp leads Kemin's global marketing; Unilever delivers on fragrance transparency pledge; Lentein protein to Canada through CK Ingredients; and Deciem founder Truaxe dead at 40.

P&G To Disclose Fragrance Ingredients Portfolio-Wide By 2020

NGOs are trumpeting P&G's fragrance disclosure announcement as a major victory for public health and a turning point for the entire consumer products industry. The initiative, which follows a similar move from Unilever in February, will provide visibility into fragrance formulae across more than 2,000 P&G products.

Fragrance Secrets Remain Safe For Now, But State Disclosure Efforts Continue

Some fragrance-disclosure bills of concern to cosmetics industry stakeholders languished in state legislative sessions this year, but others remain under consideration – in Minnesota and North Carolina, for example. IFRA North America maintains that forced disclosure of fragrance ingredients could have unintended negative consequences.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109069

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel